Question 1

What is the catalog number for Villin (VIL, VIL1, Villin1) discontinued?

Accepted Answer

The catalog number for Villin (VIL, VIL1, Villin1) discontinued is 381526.

Question 2

What sizes are available for Villin (VIL, VIL1, Villin1) discontinued?

Accepted Answer

Villin (VIL, VIL1, Villin1) discontinued is available in the following size(s): 200 µL.

Question 3

Is Villin (VIL, VIL1, Villin1) discontinued in stock?

Accepted Answer

Villin (VIL, VIL1, Villin1) discontinued is currently made to order / not held in immediate stock. Contact us for lead time.

Question 4

How long will it take to receive this product if it’s custom made?

Accepted Answer

Lead times depend on the product type: custom polyclonal antibodies typically take 12-14 weeks, monoclonal antibodies 15-17 weeks, made-to-order recombinant proteins 4-8 weeks, and made-to-order recombinant antibodies 6-8 weeks. These are estimates and may shift due to production delays.

Question 5

What is the recommended dilution for this antibody?

Accepted Answer

A recommended dilution range for each validated application is provided on the datasheet, but optimal dilution should be titrated for your specific experimental system, sample type, and detection method.

Question 6

What is the recommended storage temperature after reconstitution?

Accepted Answer

Post-reconstitution storage guidance is listed on the datasheet, typically requiring aliquoting and storage at -20°C or -80°C to preserve activity.

Villin (VIL, VIL1, Villin1) discontinued

Product Specifications

Clonality

Frequently Asked Questions

Explore Other Products

Arginase 1 (Hepatocellular Carcinoma Marker) (ARG1/1125), CF640R conjugate, 0.1mg/mL

Catenin, beta (p120) (CTNNB1/2099), CF647 conjugate, 0.1mg/mL

Endoglin / CD105 (Angiogenesis Marker) (ENG/3269), CF594 conjugate, 0.1mg/mL

Estrogen Receptor, alpha (Marker of Estrogen Dependence) (ESR1/1935), 0.2mg/mL

CD52 (Epididymis-Specific Protein 5) (CD52/2276R), CF594 conjugate, 0.1mg/mL

PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2745), CF740 conjugate, 0.1mg/mL